Showing results (1461-1470 of 1,499) with videos related to

Sort By:
Pageof 150
Trials|November 14, 2020
A study protocol for HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing cancer-related fatigue using TraditionAL Chinese Medicine: the HERBAL trialNing Yi Yap, Wei Sheng Loo, Huang Fang Zheng, et al.
Vaccine|June 24, 2015
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trialTing Wu, Yue-Mei Hu, Juan Li, et al.
Scientific Reports|March 18, 2018
Bat-mouse bone marrow chimera: a novel animal model for dissecting the uniqueness of the bat immune systemKylie Su Mei Yong, Justin Han Jia Ng, Zhisheng Her, et al.
Chemico-Biological Interactions|October 15, 2023
Hydroxychloroquine: Key therapeutic advances and emerging nanotechnological landscape for cancer mitigationLiang Ee Low, Chee Kei Kong, Wei-Hsum Yap, et al.
Human Vaccines & Immunotherapeutics|July 14, 2022
Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trialZhao-Jun Mo, Zhao-Feng Bi, Wei Sheng, et al.
BMC Plant Biology|August 13, 2021
OrchidBase 4.0: a database for orchid genomics and molecular biologyYu-Yun Hsiao, Chih-Hsiung Fu, Sau-Yee Ho, et al.
Medical Teacher|February 18, 2020
Nurturing professionalism in medical schools. A systematic scoping review of training curricula between 1990-2019Yun Ting Ong, Cheryl Shumin Kow, Yao Hao Teo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 13, 2023
Photoreceptor laminin drives differentiation of human pluripotent stem cells to photoreceptor progenitors that partially restore retina functionHwee Goon Tay, Helder Andre, Vicki Chrysostomou, et al.
Plos One|December 2, 2020
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)Cheng-Pin Chen, Yi-Chun Lin, Tsung-Chia Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical ModelsSen Zhang, Rana Anjum, Rachel Squillace, et al.
Pageof 150